Yao · American journal of respiratory cell and molecular biology 2015 · Cross-sectional comparative and ex vivo laboratory study · n=?

Disruption of Sirtuin 1-Mediated Control of Circadian Molecular Clock and Inflammation in Chronic Obstructive Pulmonary Disease.

Cited 94 times in the scientific literature.

Level 4 - case-series / case-control

Cross-sectional comparative study using human biospecimens combined with ex vivo laboratory experiments

PubMed 25905433 · doi:10.1165/rcmb.2014-0474OC · record verified 2026-08-30

What was done

Lung tissue, sputum cells, and peripheral blood mononuclear cells (PBMCs) were obtained from nonsmokers, smokers, and patients with chronic obstructive pulmonary disease (COPD). Investigators measured core molecular clock proteins (BMAL1, CLOCK, PER1, PER2, CRY1), clock-associated nuclear receptors (REV-ERBα, REV-ERBβ, RORα), and SIRT1 using immunohistochemistry, immunofluorescence, and immunoblotting. Cultured PBMCs were treated with the SIRT1 activator SRT1720 followed by LPS stimulation, and cytokine release (IL-8, IL-6, TNF-α) into the supernatant was measured at 6-hour intervals by ELISA.

What was found

The abstract reports no numerical values, effect sizes, or p-values. It reports that expression of BMAL1, PER2, CRY1, and REV-ERBα was decreased in PBMCs, sputum cells, and lung tissues of smokers and COPD patients compared to nonsmokers. In PBMCs from nonsmokers, SRT1720 mitigated LPS-induced decreases in BMAL1 and REV-ERBα. LPS exposure differentially altered the timing and amplitude of IL-8, IL-6, and TNF-α release across the three participant groups, and SRT1720 inhibited LPS-induced cytokine secretion in cultured PBMCs.

Why it matters

This study links SIRT1 reduction and molecular clock disruption to abnormal pulmonary inflammation in smokers and COPD patients. It suggests that targeting SIRT1 could help restore molecular clock regulation and modulate inflammatory pathways in COPD.

Limits

The abstract does not state the sample size (n), participant demographics, or disease stages. The mechanistic and pharmacological findings are derived from ex vivo PBMC culture rather than in vivo intervention. No quantitative estimates, baseline characteristics, or statistical dispersion metrics are provided in the abstract.

Cited by